ENDRA Life Sciences (NDRA) Net Income towards Common Stockholders (2016 - 2026)

ENDRA Life Sciences has disclosed Net Income towards Common Stockholders across 11 years of filings, most recently posting -$1.3 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 26.55% year-over-year to -$1.3 million; the TTM figure through Mar 2026 stood at -$7.3 million (up 25.24% YoY), while the FY2025 annual figure was -$7.0 million, up 38.93% from the prior year.
• Net Income towards Common Stockholders improved to -$1.3 million in Q1 2026, from -$3.2 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for NDRA reached as high as -$1.0 million in Q1 2025 and fell as low as -$4.1 million in Q4 2024.
• The 5-year median for Net Income towards Common Stockholders is -$2.8 million (2024), against an average of -$2.5 million.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders sank 184.27% — and 2025, when it jumped 62.66%.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$3.3 million in 2022, then surged by 55.63% to -$1.5 million in 2023, then slumped by 184.27% to -$4.1 million in 2024, then increased by 23.62% to -$3.2 million in 2025, then soared by 58.62% to -$1.3 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$1.3 million, -$3.2 million, and -$1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.